Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Javad Mohammadi-Asl
Total Records ( 2 ) for Javad Mohammadi-Asl
  Mohammad Reza Gholami , Ghasem Saki , Masoud Hemadi , Ali Khodadadi and Javad Mohammadi-Asl
  The purpose of this study was to test of efficacy of melatonin on the Optimizing of cryopreservation media in the testis tissue samples. Testes from neonate BALB/c mice were vitrified and then thawed under standard condition with or without the addition of 100 μM melatonin to both of vitrification and thawing solution. After that, Vitrified-thawed whole testes were digested under standard condition and subsequent viability of the cells in the suspension was analyzed using cytotoxicity kit and Apo-Brdu tunnel assay kit. The mean proportion of apoptotic testicular cells in the treated vitrified-thawed testes in comparison to no-treated ones was noted significantly (5.2±0.47 vs. 1.56±0.62, respectively). Moreover, melatonin cause decreasing the viability of the treated vitrified-thawed testicular cells in compared to no-treated vitrified-thawed testicular cells (4.78±0.46 vs. 8.39±0.76, respectively). In addition, the mean cytotoxicity of melatonin on the vitrified-thawed testicular cells was 9%. The associated reduction in healthy testicular cells in the treated vitrified-thawed testes suggests that melatonin in doses of 100 μM don’t protected testicular tissue from damaged induced in the process vitrification and thawing. However, further well-designed studies such as dosimetry melatonin and applied another cryoprotectants in the matching with melatonin are essential to offer a final conclusion.
  Hamideh Pishva , Soltan Ali Mahboob , Parvin Mehdipour , Mohammad Reza Eshraghian , Javad Mohammadi-Asl , Saeed Hosseini and Mazaher Rahmany

The alanine to threonine substitution at codon 54 in the FABP2 gene and PPARα Val162 allele have been associated with hypertriglyceridemia.

We sought to determine the prevalence of the Ala54Thr polymorphism of fatty acid binding protein (FABP) 2 gene and the Leu162/Val in exon 5 and G/C in intron7 polymorphism of peroxisome proliferator-activated receptor alpha (PPARα) gene in hypertriglyceridemic patients and their associations with blood lipid concentrations.

A total of 170 hypertriglyceridemic subjects were enrolled and genotyped for Ala54Thr, Leu162Val, and intron 7 polymorphism by the use of a polymerase chain reaction-restriction fragment length polymorphism method. Fasting blood triglyceride, total cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein (Apo)B, and ApoCIII also were determined.

We found frequency of 81.2% for the Thr54 polymorphism among hypertriglyceridemic subjects. Positive associations were observed between this polymorphism and greater blood triglyceride, very low-density lipoprotein, and ApoCIII levels and lower blood high-density lipoprotein cholesterol concentration both in men and women. However, no association was found between the Thr54 polymorphism and TC, low-density lipoprotein cholesterol, ApoB, and body mass index. Frequency of the Leu162Val polymorphism was 21.8%. The Leu162Val polymorphism was not associated with lipid and lipoprotein concentrations in hypertriglyceridemic subjects (both in men and women). The frequency of intron7 polymorphism was 55.3% in subjects studied and, except for body mass index and TC, no association was found between the intron7 allele and blood lipids ApoB, and ApoCIII.

Frequency of the Thr54 polymorphism is high in hypertriglyceridemic subjects, and the presence of this allele may increase some blood lipid and lipoprotein concentrations. In addition, the frequency of intron7 polymorphism may be greater than Leu162Val in hypertriglyceridemic patients.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility